This insight opens up new avenues for research into the pharmacodynamics of metformin in patients with PCOS and its interaction with galectin-3, a marker that has been increasingly recognized for its role in inflammatory processes and insulin resistance (Zhang et al., 2021; Zhu et al., 2023). Here, LGALS3 is linked to polycystic ovary syndrome.